Nuvation Bio Inc. (NUVB)
NYSE NYSE Primary Summary
NUVB Chart
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates
Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.17 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.15 per share a year ago.
All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy
Nuvation Bio (NUVB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nuvation Bio Inc. (NUVB) Q1 2025 Earnings Call Transcript
Nuvation Bio Inc. (NYSE:NUVB ) Q1 2025 Earnings Call May 7, 2025 4:30 PM ET Company Participants J.R. DeVita - Investor Relations David Hung - Founder, President and Chief Executive Officer Colleen Sjogren - Chief Commercial Officer Philippe Sauvage - Chief Financial Officer Conference Call Participants Gregory Renza - RBC Capital Markets Kaveri Pohlman - Clear Street Soumit Roy - Jones Research Michael Yee - Jefferies Yaron Werber - TD Cowen Operator Good afternoon and welcome to the Nuvation Bio First Quarter 2025 Financial Results and Business Update Conference Call.
Nuvation Bio Inc. Dividends
Nuvation Bio Inc. Earnings
| 5 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 5 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 4 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 7 Aug 2025 Date | | - Cons. EPS | - EPS |
| 7 Aug 2025 Date | | - Cons. EPS | - EPS |
| 5 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 5 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 4 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 7 Aug 2025 Date | | - Cons. EPS | - EPS |
| 7 Aug 2025 Date | | - Cons. EPS | - EPS |
Nuvation Bio Inc. (NUVB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Nuvation Bio Inc. ever had a stock split?
Nuvation Bio Inc. Profile
| Biotechnology Industry | Healthcare Sector | David T. Hung CEO | NYSE Exchange | 67080N101 Cusip |
| US Country | 273 Employees | - Last Dividend | - Last Split | 24 Aug 2020 IPO Date |
Overview
Nuvation Bio Inc. operates as a clinical-stage biopharmaceutical entity, dedicating its efforts toward the development of novel therapeutic candidates primarily in the field of oncology. Founded in 2018, the company is based in New York, New York, positioning itself as a pioneer in advancing cancer treatment options. Through its focus on cutting-edge research and development, Nuvation Bio Inc. aims to address the unmet medical needs in cancer care by leveraging its expertise in biopharmaceutical innovation to create a significant impact on patients' lives.
Products and Services
- NUV-868
As the lead product candidate of Nuvation Bio Inc., NUV-868 is a BD2 selective oral small molecule BET inhibitor. This innovative therapy works through epigenetic regulation of proteins pivotal in tumor growth and differentiation, including key oncogenes like c-myc. By targeting BET proteins, NUV-868 aims to disrupt the cancer cell cycle, providing a novel avenue for cancer treatment.
- NUV-1156
NUV-1156 represents another cornerstone of Nuvation Bio's portfolio. It is an AR binder Xtandi designed to tackle advanced-stage prostate cancers. This product has the unique potential to be used in earlier lines of treatment that typically involve surgical prostatectomy, offering a less invasive option for patients. By focusing on advanced prostate cancer, NUV-1156 could fill a significant treatment gap in current cancer care practices.
- Drug-Drug Conjugate (DDC) Platform
The Drug-Drug Conjugate platform developed by Nuvation Bio brings a novel approach to the drug-conjugate class of anti-cancer therapies. This technology aims to deliver anti-cancer therapeutics directly to cancer cells, ensuring more targeted treatment modalities with potentially reduced side effects. The DDC platform exemplifies Nuvation Bio's commitment to innovation in drug delivery systems for oncology.
- NUV-1176
A part of the company's diverse oncology pipeline, NUV-1176 is a PARP inhibitor focused on addressing ER+ breast and ovarian cancer. By leveraging the mechanism of PARP inhibition, NUV-1176 seeks to exploit the innate vulnerabilities of cancer cells, thereby offering a potentially effective treatment option for patients suffering from these types of cancer.
Contact Information
